title: Reduction in the size of a hepatic haemangioma after chemotherapy.
authors.forename: Manabu
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Makoto
authors.initials: M
authors.lastname: Sugawara
authors.forename: Koichi
authors.initials: K
authors.lastname: Ishiyama
authors.forename: Tutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Yuzo
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nanjo
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018240:Endodermal Sinus Tumor / Q000150:complications / Q000188:drug therapy*; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006391:Hemangioma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D007044:Hysterectomy; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008279:Magnetic Resonance Imaging; D009378:Neoplasms, Multiple Primary; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin